多臂非劣效试验设计与分析的建议:方法学综述与现状回顾
该文通过综述四大数据库文献,梳理多臂非劣效(MANI)试验在设计阶段假设构建、分析阶段多重检验校正及异质性方差处理等方面的问题,并结合65项已发表MANI试验的实践情况提出设计与分析建议。
要点
- MANI试验需同时兼顾多臂比较与非劣效性两方面的设计与分析要求。
- 多重检验校正方法(更高效P值校正 vs 近似校正CI)尚缺乏共识。
- 已发表的65项MANI试验中,39项需要多重检验校正,其中31项进行了校正。
核心结论
- 现有MANI试验对本文提出的问题有所认识,但极少满足所概述的建议标准。
- 未来试验应参考本文建议,并明确界定和论证其设计与分析技术的选择。
研究设计与样本
- 综合文献综述,覆盖四个数据库,检索与MANI试验相关的出版物。
- 文献分为方法学文献与试验文献,分别用于考察所需设计分析要点及实践现状。
- 共识别65项既往MANI试验实例。
主要发现
- 识别出多个若未妥善处理可能导致FWER、把握度或偏倚问题的要点。
- 问题范围从设计阶段的试验假设构建到分析阶段潜在异质性治疗方差的考量。
- 分析阶段多重检验校正是关键关注点之一。
- 关于呈现和解读MANI试验结果时是否偏好更高效的P值校正方法而非近似校正CI,尚缺乏共识。
- 65项MANI试验中,39项被判定需要多重检验校正,其中31项进行了校正。
关键数值与推荐
- 试验通常偏好使用简单、熟知的方法进行设计与分析。
- 许多试验对FWER膨胀和把握度选择有一定认识,但似乎未考虑相关问题。
- 许多试验未对其选择的设计与分析方法提供充分定义。
临床怎么用
- 设计MANI试验时应从多臂与非劣效性双重视角考虑设计与分析问题。
- 应明确界定并论证所选的试验设计与分析技术。
- 应关注分析阶段的多重检验校正及潜在异质性治疗方差。
局限性
- 本文为文献综述,未报告原始研究数据或样本量等定量结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Multi-arm non-inferiority (MANI) trials, here defined as non-inferiority trials with multiple experimental treatment arms, can be useful in situations where several viable treatments exist for a disease area or for testing different dose schedules. To maintain the statistical integrity of such trials, issues regarding both design and analysis must be considered, from both the multi-arm and the non-inferiority perspectives. Little guidance currently exists on exactly how these aspects should be addressed and it is the aim of this paper to provide recommendations to aid the design of future MANI trials. METHODS: A comprehensive literature review covering four databases was conducted to identify publications associated with MANI trials. Literature was split into methodological and trial publications in order to investigate the required design and analysis considerations for MANI trials and whether they were being addressed in practice. RESULTS: A number of issues were identified that if not properly addressed, could lead to issues with the FWER, power or bias. These ranged from the structuring of trial hypotheses at the design stage to the consideration of potential heterogeneous treatment variances at the analysis stage. One key issue of interest was adjustment for multiple testing at the analysis stage. There was little consensus concerning whether more powerful p value adjustment methods were preferred to approximate adjusted CIs when presenting and interpreting the results of MANI trials. We found 65 examples of previous MANI trials, of which 31 adjusted for multiple testing out of the 39 that were adjudged to require it. Trials generally preferred to utilise simple, well-known methods for study design and analysis and while some awareness was shown concerning FWER inflation and choice of power, many trials seemed not to consider the issues and did not provide sufficient definition of their chosen design and analysis approaches. CONCLUSIONS: While MANI trials to date have shown some awareness of the issues raised within this paper, very few have satisfied the criteria of the outlined recommendations. Going forward, trials should consider the recommendations in this paper and ensure they clearly define and reason their choices of trial design and analysis techniques.
引用
- Emmerson J, Todd S, Brown JM, et al. Recommendations for designing and analysing multi-arm non-inferiority trials: a review of methodology and current practice. Trials. 2021. PMID: 34174937. doi:10.1186/s13063-021-05364-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。